 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
3 News |  |
| «123456789 |
- Opdivo (nivolumab) / Ono Pharma, BMS, AK104 / Akesobio
[VIRTUAL] Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies (Channel 2) - Jul 21, 2020 - Abstract #ESMO2020ESMO_1210;
P1a/1b
Funding: Akesobio Australia Pty Ltd. Clinical trial identification: NCT03261011.
- || Kaitanni (cadonilimab) / Akesobio
Enrollment open, Metastases: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov) - Jul 20, 2020
P2, N=40, Recruiting, Sponsor: Akeso
Clinical trial identification: NCT03261011. Not yet recruiting --> Recruiting
- |||| Kaitanni (cadonilimab) / Akesobio
New P1/2 trial: A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov) - Jun 22, 2020
P1/2, N=80, Recruiting, Sponsor: Akeso
- || Kaitanni (cadonilimab) / Akesobio
New P1/2 trial, Combination therapy, Metastases: AK104-206: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 22, 2020
P1/2, N=30, Recruiting, Sponsor: Akeso
- || Kaitanni (cadonilimab) / Akesobio
New P2 trial, Metastases: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov) - May 7, 2020
P2, N=40, Not yet recruiting, Sponsor: Akeso
- |||| AK104 / Akesobio
Bispecifics @ #AACR20 | Bispecific abstract (CT120) for AK104 PD-1 x CTLA-4 BiAb (Twitter) - Apr 27, 2020
- ||| Kaitanni (cadonilimab) / Akesobio, ligufalimab (AK117) / Akesobio
New P1 trial, Combination therapy, Monotherapy, Metastases: AK117-101: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104 (clinicaltrials.gov) - Apr 15, 2020
P1, N=159, Not yet recruiting, Sponsor: Akeso
- Opdivo (nivolumab) / Ono Pharma, BMS, AK104 / Akesobio
[VIRTUAL] AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in a phase Ib trial in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_120;
P1/2
AK104 in combination with mXELOX had a manageable safety profile and encouraging antitumor activities in pts with advanced G/GEJ adenocarcinoma regardless of PD-L1 status. Enrollment is currently ongoing for expansion cohort at 6 mg/kg and enrollment for 10 mg/kg cohort in the escalation phase will be started in early Feb, 2020.
- ||| KN046 / Alphamab, AK104 / Akesobio
Clinical: Both AK104 and KN046 have shown improved safety profile compared to anti-CTLA4，but no significant improved efficacy than single anti-PD-1/-L1 @JacobPlieth @ByAmyBrown (Twitter) - Feb 17, 2020
- |||| Kaitanni (cadonilimab) / Akesobio
New P2 trial, Metastases: A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jan 6, 2020
P2, N=140, Not yet recruiting, Sponsor: Akeso
- methylprednisolone oral / Generic mfg., AK104 / Akesobio
[VIRTUAL] IMMUNE CHECKPOINT INHIBITOR INDUCED MYOCARDITIS MIMICKING MYOCARDIAL INFARCTION (eAbstract Virtual Hall) - Dec 22, 2019 - Abstract #ACC2020ACC_4635;
Clinical decisions require delicate differential diagnosis based on clinical, EKG and cardiac enzyme changes.Case: A 59-year-old male with squamous cell lung cancer presented for the scheduled 4th cycle of AK104 (an anti-PD-1 and CTLA-4 antibody) therapy...1H) and following tests showed elevated troponin and normal cardiac systolic function.Decision‐making: He was referred to our cardiology department 5 hours after 120mg of methylprednisolone was given... This case highlights ICI induced myocarditis could mimic acute MI and early diagnose and steroids therapy are crucial.
- ||||| AK104 / Akesobio
Clinical: Markman, Minaj #SITC19 #sitc2019 AK104, Akeso PD-1 x CTLA-4 bispecific Ph1a 55 patients enrolled (Twitter) - Nov 9, 2019
- AK104 / Akesobio
A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors (Prince George's Exhibition Hall C) - Oct 2, 2019 - Abstract #SITC2019SITC_315;
P1a/1b
Enrolment is currently ongoing at 10.0 mg/kg and in dose expansion cohorts. Updated data, including PK, Ki67, RO and other biomarkers based on pair biopsies will be presented.
- AK104 / Akesobio
A phase Ib/II study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with mXELOX as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2485;
P1/2
Legal entity responsible for the study: Peking University Cancer Hospital & Institute, Beijing, China. Funding: Akeso Biopharma, Inc., Zhongshan, China.
- |||| Kaitanni (cadonilimab) / Akesobio
New P1/2 trial, Combination therapy, Metastases: COMPASSION-03: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma (clinicaltrials.gov) - Feb 25, 2019
P1/2, N=112, Recruiting, Sponsor: Akeso
- | Kaitanni (cadonilimab) / Akesobio
Enrollment open, Metastases: Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 22, 2017
P1a/1b, N=153, Recruiting, Sponsor: Akesobio Australia Pty Ltd
Funding: Akeso Biopharma, Inc., Zhongshan, China. Not yet recruiting --> Recruiting
- | Kaitanni (cadonilimab) / Akesobio
New P1 trial, Metastases: Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 23, 2017
P1a/1b, N=153, Not yet recruiting, Sponsor: Akesobio Australia Pty Ltd